Nuwellis, Inc. Stock Plummets to New 52-Week Low of $3.65

Nuwellis, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.65 as of September 18, 2025. This marks a significant decline, with the stock's performance over the past year showing a decrease of 47.7%, contrasting sharply with the S&P 500's gain of 17.14% during the same period.
The company's financial metrics indicate ongoing challenges. Nuwellis has reported a quarterly net sales figure of USD 1.73 million, reflecting a decline of 21.47%. Additionally, the pre-tax profit has seen a substantial drop, reported at USD -13.45 million, which is a staggering decrease of 261.58%. The company's debt-to-equity ratio stands at 0.47, suggesting a moderate level of leverage, but its ability to service this debt appears weak, as indicated by a negative EBIT to interest ratio of -8.96.

With a market capitalization of just USD 4 million, Nuwellis continues to face significant hurdles in its operational performance, as evidenced by its negative EBITDA and a price-to-book ratio of -0.48. The stock's previous 52-week high was USD 175.98, highlighting the extent of its recent decline.